UK-based TeraView, the world’s first company devoted to the application of Terahertz (THz) light for imaging and spectroscopy, opened its first overseas office in Dayton last year. Fresh from raising $5.5 million of new investment, the company is now expanding their facility in the Institute for the Development and Commercialization of Advanced Sensor Technology (IDCAST) to offer contract analytical services to U.S. pharmaceutical companies. From 1st March, a TPI Imaga 2000 tablet imaging system will be available for demonstrations or rental and adds strength to the existing spectroscopy and imaging capability within IDCAST. The company also plans, in conjunction with IDCAST, to run a series of terahertz workshop aimed at showing how terahertz can be best used in pharmaceutical development..
“There is an impressive concentration of Terahertz systems and technology in this region,” said TeraView CEO Don Arnone last March. “Our long and productive associations with world-class researchers in this region, who we support and work with as collaborators and customers, make Ohio ideally suited for this facility.” TeraView has worked with scientists at Miami University, Ohio State, and Wright State, among others, and are eager to establish new collaborations with other institutions.
TeraView’s proprietary platform uses the THz spectrum between light and radio waves and offers the advantage of being non-invasive and non-destructive. Past studies have demonstrated how THz uniquely and non destructively provides chemical and 3D structural information in a diverse range of applications, including the contents of drug tablets, and other objects normally invisible to conventional detection techniques.
According to Sr. VP Sales and Marketing Ian Grundy, the company is moving more of their own equipment into rented IDCAST space and wants to expand contract analysis services. “Our contract analysis product gives pharma companies access to Terahertz technology and data to develop new products or help resolve quality issues, particularly at scale-up,” he said.
In conjunction with UK institutions, using a proprietary terahertz probe TeraView also has conducted in-vivo trials on the detection of various cancers using a THz probe. Work has been primarily done on skin and breast cancers. The results to-date have shown good specificity and selectivity. The company has also supplied its medical probe system to other researchers and is actively looking to expand its collaborations in the area.